Monte Rosa Therapeutics, Inc. (GLUE) Stock

Monte Rosa Therapeutics, Inc. (GLUE) is a Healthcare stock trading at $18.30 (as of 2026-06-18), with a market capitalization of $1.67B and a trailing P/E of -12.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company developing small-molecule precision medicines that aim to selectively degrade therapeutically relevant proteins using natural cellular mechanisms. Its pipeline includes an oral molecular-glue degrader for GSPT1 and programs targeting CDK2, NEK7, VAV1, and BCL11A for cancers, inflammatory diseases, autoimmune conditions, and hemoglobinopathies.

Valuation — source: SEC EDGAR (first-party)
Price	$18.30
Market Cap	$1.67B
P/E Ratio	-12.3
EV / EBITDA	-9.8
Price / Book	2.95
Price / Sales	35.86
Dividend Yield	0.0%
DCF Value (model)	$-4.17
DCF Upside vs Price	-122.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$123.67M
Net Margin	-31.2%
Return on Equity	-24.9%
Current Ratio	9.54
Revenue Growth (YoY)	63.5%
FCF Growth (YoY)	-172.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	3.34 (safe)

Valuation vs Sector & Industry
Stock P/E	-12.3
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-158.8%
vs Industry	-171.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	NEA Management Company, LLC ($126.54M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Markus Warmuth
Employees	142
Country	US
IPO Date	2021-06-24

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.